New clues that may connect the circulating irisin levels to glucose status and bone turnover markers in postmenopausal women (project IRI-OP-OB)

Sorina Schipor; Dana Manda; Luminita Suveica; Oana-Claudia Sima; Veronica Cumpata; Daniela Galea-Abdusa; Maria-Mihaela Vovc; Ana Popescu; Mara Carsote

doi:10.1530/endoabs.110.EP208

EP208

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP208 | DOI: 10.1530/endoabs.110.EP208

ECEESPE2025 ePoster Presentations Bone and Mineral Metabolism (142 abstracts)

New clues that may connect the circulating irisin levels to glucose status and bone turnover markers in postmenopausal women (project IRI-OP-OB)

Sorina Schipor ¹ , Dana Manda ¹ , Luminita Suveica ² , Oana-Claudia Sima ¹ , Veronica Cumpata ² , Daniela Galea-Abdusa ² , Maria-Mihaela Vovc ² , Ana Popescu ² & Mara Carsote ¹

Author affiliations

¹"C. I. Parhon" National Institute of Endocrinology, Bucharest, Romania; ²“Nicolae Testemitanu” State University of Medicine and Pharmacy, Chisinau, Moldova

JOINT2704

Background: Irisin, a muscle-released hormone, interferes with the metabolism regulation, including settling the metabolic rate, and recently proved being pro-active in the mater of bone formation.

Objective: To check the circulating irisin levels in menopausal women in relationship with glucose profile assays and bone turnover markers on two different age groups.

Methods: This was a bi-centric, transversal, clinical study, in menopausal women without prior diagnosis of osteoporosis. Inclusion criteria were: confirmation of menopausal status and age over 50. Exclusion criteria were: insulin therapy, specific anti-osteoporotic medication, active cancers or functioning endocrine tumors at any gland, current exposure to glucocorticoid or GLP-1 agonists, end-stage CKD. The protocol included blood testing for irisin (ELISA, MyBioSource), bone turnover markers: osteocalcin, P1NP, beta-CrossLaps (ECLIA, Roche), fasting glucose (photometry, Abbott), insulin (CLIA, Beckman Coulter) and 2-hour assays amid oral 75 g-glucose tolerance test and A1c glycated hemoglobin (photometry, Roche).

Results: Two age groups: A (older than 50 to 60 y, n =18) and B (older than 60 to 70 y, n=19) were analyzed. Group A (55.61 ± 2.99 y) versus group B (66.11 ± 2.92 y) showed no significant differences with respect to irisin, osteocalcin, P1NP, beta-CrossLaps, fasting glycaemia, insulin, HbA1c. We found no correlation between irisin and bone turnover markers but a statistically significant positive correlation with 2-h glucose in each group (r=0.394, P = 0.042 and r=0.462, P = 0.028), and fasting insulin plus 2-h insulin for group A (r=0.543, P = 0.005 and r=0.41, P = 0.033). A borderline significance was established in group A with respect to irisin-HbA1c correlation (r=0.294, P = 0.08).

Discussions and conclusions: So far, the correlation with glucose profile markers seems more important than the correlation with bone turnover markers. Circulating irisin levels are relevant for the muscle-bone-fat cross talk and they might serve as metabolic biomarkers.